Cargando…
Local recurrence management of extremity soft tissue sarcoma
Patients diagnosed with soft tissue sarcoma (STS) present a number of challenges for physicians, due to the vast array of subtypes and aggressive tumor biology. There is currently no agreed-upon management strategy for these tumors, which has led to the ongoing debate surrounding how frequently surv...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441250/ https://www.ncbi.nlm.nih.gov/pubmed/37526250 http://dx.doi.org/10.1530/EOR-23-0095 |
_version_ | 1785093343016910848 |
---|---|
author | Serban, Bogdan Cretu, Bogdan Cursaru, Adrian Nitipir, Cornelia Orlov-Slavu, Cristina Cirstoiu, Catalin |
author_facet | Serban, Bogdan Cretu, Bogdan Cursaru, Adrian Nitipir, Cornelia Orlov-Slavu, Cristina Cirstoiu, Catalin |
author_sort | Serban, Bogdan |
collection | PubMed |
description | Patients diagnosed with soft tissue sarcoma (STS) present a number of challenges for physicians, due to the vast array of subtypes and aggressive tumor biology. There is currently no agreed-upon management strategy for these tumors, which has led to the ongoing debate surrounding how frequently surveillance scans should be performed following surgery. However, advances in multidisciplinary care have improved patient outcomes over recent years. The early detection of local recurrence reflects a more aggressive tumor, even in association with the same histopathologic entity. Treating the local recurrence of extremity STS is a difficult clinical challenge. The goal should be to salvage limbs when possible, with treatments such as resection and irradiation, although amputation may be necessary in some cases. Regional therapies such as high-intensity, low-dose or interleukin-1 receptor antagonist treatment are appealing options for either definitive or adjuvant therapy, depending on the location of the disease’s recurrence. The higher survival rate following late recurrence may be explained by variations in tumor biology. Since long-term survival is, in fact, inferior in patients with high-grade STS, this necessitates the implementation of an active surveillance approach. |
format | Online Article Text |
id | pubmed-10441250 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-104412502023-08-22 Local recurrence management of extremity soft tissue sarcoma Serban, Bogdan Cretu, Bogdan Cursaru, Adrian Nitipir, Cornelia Orlov-Slavu, Cristina Cirstoiu, Catalin EFORT Open Rev Oncology Patients diagnosed with soft tissue sarcoma (STS) present a number of challenges for physicians, due to the vast array of subtypes and aggressive tumor biology. There is currently no agreed-upon management strategy for these tumors, which has led to the ongoing debate surrounding how frequently surveillance scans should be performed following surgery. However, advances in multidisciplinary care have improved patient outcomes over recent years. The early detection of local recurrence reflects a more aggressive tumor, even in association with the same histopathologic entity. Treating the local recurrence of extremity STS is a difficult clinical challenge. The goal should be to salvage limbs when possible, with treatments such as resection and irradiation, although amputation may be necessary in some cases. Regional therapies such as high-intensity, low-dose or interleukin-1 receptor antagonist treatment are appealing options for either definitive or adjuvant therapy, depending on the location of the disease’s recurrence. The higher survival rate following late recurrence may be explained by variations in tumor biology. Since long-term survival is, in fact, inferior in patients with high-grade STS, this necessitates the implementation of an active surveillance approach. Bioscientifica Ltd 2023-08-01 /pmc/articles/PMC10441250/ /pubmed/37526250 http://dx.doi.org/10.1530/EOR-23-0095 Text en © the author(s) https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Oncology Serban, Bogdan Cretu, Bogdan Cursaru, Adrian Nitipir, Cornelia Orlov-Slavu, Cristina Cirstoiu, Catalin Local recurrence management of extremity soft tissue sarcoma |
title | Local recurrence management of extremity soft tissue sarcoma |
title_full | Local recurrence management of extremity soft tissue sarcoma |
title_fullStr | Local recurrence management of extremity soft tissue sarcoma |
title_full_unstemmed | Local recurrence management of extremity soft tissue sarcoma |
title_short | Local recurrence management of extremity soft tissue sarcoma |
title_sort | local recurrence management of extremity soft tissue sarcoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441250/ https://www.ncbi.nlm.nih.gov/pubmed/37526250 http://dx.doi.org/10.1530/EOR-23-0095 |
work_keys_str_mv | AT serbanbogdan localrecurrencemanagementofextremitysofttissuesarcoma AT cretubogdan localrecurrencemanagementofextremitysofttissuesarcoma AT cursaruadrian localrecurrencemanagementofextremitysofttissuesarcoma AT nitipircornelia localrecurrencemanagementofextremitysofttissuesarcoma AT orlovslavucristina localrecurrencemanagementofextremitysofttissuesarcoma AT cirstoiucatalin localrecurrencemanagementofextremitysofttissuesarcoma |